よむ、つかう、まなぶ。
04資料1-2 森野委員提出資料（成人用肺炎球菌ワクチンファクトシート追補版） (31 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_76211.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第36回 9／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
vaccination. Lancet 2011; 378(9807): 1962–73.
17.
Esposito S, Principi N, Group EVS. Direct and indirect effects of the 13-valent pneumococcal
conjugate vaccine administered to infants and young children. Future Microbiol 2015; 10(10): 1599–607.
18.
Amin-Chowdhury Z, Groves N, Sheppard CL, et al. Invasive pneumococcal disease due to 22F and
33F in England: A tail of two serotypes. Vaccine 2021; 39(14): 1997–2004.
19.
Duvvuri VR, Deng X, Teatero S, et al. Population structure and drug resistance patterns of emerging
non-PCV-13 Streptococcus pneumoniae serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada.
Infect Genet Evol 2016; 42: 1–8.
20.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal
pneumonia in adults. N Engl J Med 2015; 372(12): 1114–25.
21.
Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-
Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk
Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis 2022;
9(3): ofab605.
22.
Wierzbowski A, Pless R, Hildebrand KJ. Summary of the NACI Statement on Public Health Level
Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-valent and 20valent Conjugate Vaccines. Can Commun Dis Rep 2023; 49(23): 81–6.
23.
Platt H, Omole T, Cardona J, et al. Safety, tolerability, and immunogenicity of a 21-valent
pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active
comparator-controlled, multicentre, US-based trial. Lancet Infect Dis 2023; 23(2): 233–46.
24.
Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among
U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
MMWR Morb Mortal Wkly Rep 2024; 73(36): 793–8.
25.
Micoli F, Romano MR, Carboni F, Adamo R, Berti F. Strengths and weaknesses of pneumococcal
conjugate vaccines. Glycoconj J 2023; 40(2): 135–48.
26.
Sings HL, Gessner BD, Wasserman MD, Jodar L. Pneumococcal Conjugate Vaccine Impact on
Serotype 3: A Review of Surveillance Data. Infect Dis Ther 2021; 10(1): 521–39.
27.
Ul Haq MZ, Irfan H, Shah MSU, et al. Immunogenicity, safety and tolerability of 15-valent
pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in
healthy infants: A systematic review and meta-analysis. Vaccine: X 2025; 24: 100654.
28.
Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination:
what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis 2015; 34(1):
19–31.
29.
Shimbashi R, Arima Y, Yahara K, et al. A pluralistic approach to interpreting surveillance data: The
likely decline in the occurrence of invasive pneumococcal disease in Japan during the COVID-19 pandemic.
Ann Epidemiol 2025; 108: 63–70.
30.
Kajihara T, Yahara K, Kamigaki T, et al. Effects of coronavirus disease 2019 on the spread of
respiratory-transmitted human-to-human bacteria. J Infect 2024; 89(2): 106201.
31
17.
Esposito S, Principi N, Group EVS. Direct and indirect effects of the 13-valent pneumococcal
conjugate vaccine administered to infants and young children. Future Microbiol 2015; 10(10): 1599–607.
18.
Amin-Chowdhury Z, Groves N, Sheppard CL, et al. Invasive pneumococcal disease due to 22F and
33F in England: A tail of two serotypes. Vaccine 2021; 39(14): 1997–2004.
19.
Duvvuri VR, Deng X, Teatero S, et al. Population structure and drug resistance patterns of emerging
non-PCV-13 Streptococcus pneumoniae serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada.
Infect Genet Evol 2016; 42: 1–8.
20.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal
pneumonia in adults. N Engl J Med 2015; 372(12): 1114–25.
21.
Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-
Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk
Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis 2022;
9(3): ofab605.
22.
Wierzbowski A, Pless R, Hildebrand KJ. Summary of the NACI Statement on Public Health Level
Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-valent and 20valent Conjugate Vaccines. Can Commun Dis Rep 2023; 49(23): 81–6.
23.
Platt H, Omole T, Cardona J, et al. Safety, tolerability, and immunogenicity of a 21-valent
pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active
comparator-controlled, multicentre, US-based trial. Lancet Infect Dis 2023; 23(2): 233–46.
24.
Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among
U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
MMWR Morb Mortal Wkly Rep 2024; 73(36): 793–8.
25.
Micoli F, Romano MR, Carboni F, Adamo R, Berti F. Strengths and weaknesses of pneumococcal
conjugate vaccines. Glycoconj J 2023; 40(2): 135–48.
26.
Sings HL, Gessner BD, Wasserman MD, Jodar L. Pneumococcal Conjugate Vaccine Impact on
Serotype 3: A Review of Surveillance Data. Infect Dis Ther 2021; 10(1): 521–39.
27.
Ul Haq MZ, Irfan H, Shah MSU, et al. Immunogenicity, safety and tolerability of 15-valent
pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in
healthy infants: A systematic review and meta-analysis. Vaccine: X 2025; 24: 100654.
28.
Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination:
what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis 2015; 34(1):
19–31.
29.
Shimbashi R, Arima Y, Yahara K, et al. A pluralistic approach to interpreting surveillance data: The
likely decline in the occurrence of invasive pneumococcal disease in Japan during the COVID-19 pandemic.
Ann Epidemiol 2025; 108: 63–70.
30.
Kajihara T, Yahara K, Kamigaki T, et al. Effects of coronavirus disease 2019 on the spread of
respiratory-transmitted human-to-human bacteria. J Infect 2024; 89(2): 106201.
31